Shares of bluebird bio, Inc. (NASDAQ:BLUE – Get Free Report) have earned an average recommendation of “Hold” from the twelve analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $5.87.
A number of brokerages recently weighed in on BLUE. Royal Bank of Canada reiterated a “sector perform” rating and issued a $6.00 target price on shares of bluebird bio in a report on Wednesday, March 27th. Wedbush dropped their target price on shares of bluebird bio from $1.72 to $1.68 and set a “neutral” rating for the company in a research report on Tuesday, March 19th. Bank of America decreased their price objective on shares of bluebird bio from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, December 21st. Wells Fargo & Company reduced their target price on shares of bluebird bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Wednesday, March 27th. Finally, William Blair reiterated a “market perform” rating on shares of bluebird bio in a report on Tuesday, January 9th.
Read Our Latest Stock Analysis on BLUE
Institutional Trading of bluebird bio
bluebird bio Stock Down 1.1 %
NASDAQ:BLUE opened at $0.95 on Tuesday. The company has a market cap of $104.20 million, a P/E ratio of -1.31 and a beta of 0.74. The firm’s 50 day moving average is $1.27 and its two-hundred day moving average is $2.07. bluebird bio has a fifty-two week low of $0.88 and a fifty-two week high of $5.53.
bluebird bio Company Profile
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Recommended Stories
- Five stocks we like better than bluebird bio
- EV Stocks and How to Profit from Them
- Comprehensive PepsiCo Stock Analysis
- What Are the U.K. Market Holidays? How to Invest and Trade
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Why is the Ex-Dividend Date Significant to Investors?
- Bear Market Funds to Watch This Year
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.